SCHEMBL23976149

SCHEMBL23976149

Cc1cc(Cl)cc(-c2nc3c(c(N(C)CC(=O)NC(C)(C)C)n2)CCC3)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
PDE4B Q07343 3/20 0.33
PDE10A Q9Y233 1/20 0.33
HDAC1 Q13547 4/20 0.33
HDAC8 Q9BY41 4/20 0.33
HDAC6 Q9UBN7 4/20 0.33
C5AR1 P21730 1/20 0.33
CYP1A2 P05177 1/20 0.32
GAA P10253 1/20 0.32
ALDH1A1 P00352 5/20 0.32
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
MAPT P10636 2/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 1/20 0.31
MAPK1 P28482 1/20 0.31
ADORA3 P0DMS8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23976157 0.86 POLB (0.36) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL26229053 0.85 MEN1 (0.36) MEN1KMT2APOLBPDE10AHDAC1
SCHEMBL23975720 0.85 MEN1 (0.40) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL26229049 0.84 HDAC1 (0.38) MEN1KMT2APOLBPDE10AHDAC1
SCHEMBL23976958 0.84 MEN1 (0.36) MEN1KMT2APOLBPDE10AHDAC1
SCHEMBL23976880 0.84 HDAC1 (0.38) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL26228682 0.83 KMT2A (0.37) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL30118828 0.83 KMT2A (0.37) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL23975975 0.83 KMT2A (0.37) MEN1KMT2APOLBPDE4BPDE10A
SCHEMBL23975803 0.83 POLB (0.36) MEN1KMT2APOLBPDE4BPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
EP-4143178-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed
EP-4142732-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 MEN1 2863/4885KMT2A 4375/4885POLB 355/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI MEN1 2553/4885KMT2A 4677/4885POLB 480/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI MEN1 2553/4885KMT2A 4677/4885POLB 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.